 Part B will evaluate the optimized doseschedule identified in Part A of the study in patients with 1 BRCA12 mutant cancers with previous disease progression on PARP inhibitor monotherapy, or 2 advanced sporadic tumours e.g. TNBC, CRPC, HGSOC and tumours with somatic mutations or other aberrations known to result in a hyperactivated PI3K-AKT pathway. 